If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
236
results.
Updated on
14/07/2025 [06:52:00]
Results 100 to 125 of 236
Absstract of: CN119630706A
The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancer, in a subject. The combination therapy comprises (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) a chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.
Absstract of: CN120241596A
本发明提供了一种动物眼用制剂及其制备方法，属于药物制剂技术领域。本发明提供的动物眼用制剂按质量含量数计，包括以下组分：壳聚糖包覆的盐酸莫西沙星纳米颗粒0.1～5％、泊洛沙姆18810～40％、渗透压调节剂0.1～2％和余量的注射用水。本发明提供的动物眼用制剂采用壳聚糖包覆的盐酸莫西沙星纳米颗粒，能够缓释盐酸莫西沙星，延长药效；本发明通过添加泊洛沙姆188作为凝胶剂，能够在其低临界溶解温度以下以液体形式存在，在环境温度升高后进行凝胶化，提升眼用制剂使用的舒适度。实施例结果显示，本发明提供的动物眼用制剂药效时间长，刺激性小。
Absstract of: CN120241654A
本发明公开了基于癌细胞膜修饰的仿生纳米粒子及其制备方法与应用，属于纳米载药技术领域，具体涉及一种基于癌细胞膜修饰的仿生纳米粒子，包括：载体，负载于载体上的效用剂，以及外层包覆的癌细胞膜；载体中含有CeO2以及MoS2，CeO2为空心结构，MoS2结合于CeO2的空心结构上。本发明制备得到的基于癌细胞膜修饰的仿生纳米粒子的靶向性好、抗肿瘤活性好、细胞毒性低、抑制肿瘤生长、肿瘤靶向性蓄积能力好、循环时间长、可以有效杀死肿瘤细胞。
Absstract of: CN120241773A
本发明提供了一种抑制人PPP1R3B基因表达的siRNA试剂、组合物及其应用，属于生物医药技术领域。在本发明中所述抑制人PPP1R3B基因表达的siRNA试剂包括siRNA和递送系统；所述siRNA为由一条正义链和一条反义链组成的双链RNA分子，所述递送系统为脂质纳米颗粒递送系统或GalNAc递送系统。本发明通过对人PPP1R3B基因设计siRNA序列，并通过对siRNA序列进行化学修饰与递送系统优化，解决了现有技术中的脱靶效应、递送效率低及体内稳定性差等问题，实现了对该靶点的全方位保护。
Absstract of: CN120241641A
本发明属于纳米生物学技术领域，公开了一种乏氧响应性脂质纳米递送系统及其制备方法和应用。该方法包括步骤：将2‑(4‑氯‑2‑硝基苯基)乙酸、2‑(7‑氮杂苯并三氮唑)‑N,N,N',N'‑四甲基脲六氟磷酸酯和N,N‑二异丙基乙胺、吡啶混合搅拌反应，加入mPEG‑NH2搅拌反应，再加入二硬脂酰磷脂酰乙醇胺、醋酸钯、4,5‑双二苯基膦‑9,9‑二甲基氧杂蒽和碳酸铯，120℃回流反应过夜，透析、离心，收集上清，冷冻干燥得DNP；将二硬酯酰磷脂酰胆碱、胆固醇、DNP、索拉非尼和米托蒽醌溶解在无水乙醇中，避光搅拌溶解；旋干形成薄膜，加入PBS后水化，冰水浴中超声；挤出膜得到乏氧响应性脂质纳米递送系统。
Absstract of: CN120241647A
本发属于无机仿生材料用于肿瘤靶向药物领域，具体公开了一种光磁原位自组装的光热气级联仿生纳米反应器、制备方法与应用。所述的纳米反应器由最内部的球状羰基铁粉、附着于球状羰基铁粉表面的海胆乳突状Fe3O4、最外层包裹的血小板膜组成；进一步公开的制备方法：1)羰基铁粉(CIP)的制备：通过高温高压的条件下将海绵铁单质转化为多羰基铁，再通入CO退火得到羰基铁粉；2)CIP@Fe3O4的制备：采用原位共沉淀的方式，利用NH3对羰基的保护将四氧化三铁沉积在羰基铁粉表面；3)CIP@Fe3O4@PM的制备：将提取出的血小板膜通过超声和挤出法包裹在CIP@Fe3O4的表面。本发明所述的CIP@Fe3O4@PM纳米反应器具有光磁原位自组装能力与光热气级联的特性用于加强肿瘤诊疗效果。
Absstract of: WO2024112652A1
The present disclosure provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.
Absstract of: CN120241664A
本发明公开了一种沙美特罗贴剂及其制备方法。本发明首先将沙美特罗预分散在乳液中，单体乙酸乙烯酯与聚乙烯醇在聚合的同时将沙美特罗包裹在聚合物中，形成可降解的亲油亲水的聚合物纳米粒子，然后加入再加入渗透剂、压敏胶等将其制备成贴片。本发明首先采用亲水亲油的聚合物对沙美特罗进行包封，两亲性的聚合物与贴片中的辅料有更好的相容性，包裹药物后可使药物更加均匀的分布于贴片，同时沙美特罗具有较好的亲脂性，结合聚合物较好的亲油亲水性，从而所制备的贴剂对皮肤具有更好的透过性，同时避免了药物从过饱和状态重新析晶的问题，使得贴片作用效果更好。
Absstract of: CN120241649A
本申请实施例提出一种PSO/PTX靶向复合纳米粒及其制备方法和用途。述制备方法包括：将磷脂组合物溶于第一有机溶剂中，溶解后加入水和乳化剂，混合均匀得到水相；其中，所述磷脂组合物包括磷脂和改性磷脂；将PLGA溶于第二有机溶剂中，溶解后加入PTX、PSO和SPIONs@OA，混合均匀得到有机相；将有机相加入水相中，经超声乳化、蒸发除去有机溶剂再过滤后得到PSO/PTX靶向复合纳米粒。本申请实施例所制备的PSO/PTX靶向复合纳米粒，首次提出将补骨脂素与紫杉醇共载于超顺磁聚合物脂质纳米粒，该PSO/PTX靶向复合纳米粒兼具磁靶向、长循环与缓释功能，提示该PSO/PTX靶向复合纳米粒在制备治疗乳腺癌药物中具有良好的应用前景。
Absstract of: CN120249214A
本发明公开了一种靶向FAP的抗炎CAR‑巨噬细胞及其制备方法和在制备治疗纤维化疾病的药物中的应用，属于生物医药技术领域。本发明提供了FAP特异性的嵌合抗原受体及其mRNA表达载体、His标记的STING信号通路抑制剂及其mRNA表达载体。通过LNP递送CAR mRNA以及TRIM13mNRA可有效实现体内外巨噬细胞编辑，赋予其靶向吞噬FAP阳性细胞的能力，同时促进巨噬细胞抗炎表型极化改善局部炎症，协同遏制炎症驱动的纤维化进展。
Absstract of: US2024390484A1
The disclosure relates to the method of lyophilizing RNA and mixing with a liquid LNP solution, e.g., to make an RNA vaccine or therapeutic. Included are methods for preparing and administering the vaccine or therapeutic.
Absstract of: CN120241651A
本发明公开了一种基于金属离子介导复合多糖基稳态化益生菌负载体及其制备方法和应用，属于微生物技术领域。本发明采用海藻酸钠与金属离子通过非共价超分子相互作用配位自组装形成金属离子‑海藻酸盐骨骼网络，进一步填充功能化瓜尔胶，推动纳米级团聚体自发沉积在菌体表面，生成具备优异的黏附性能和稳态性能的复合多糖外衣，实现益生菌独立包覆。金属离子的存在增加了生物材料对包被的益生菌的亲和力，瓜尔胶赋予益生菌递送系统良好的粘附特性。本发明的益生菌负载体简化了现有细胞表面修饰技术的操作步骤，生物材料使用量减少的同时致密度提升，可以保护细胞免受胃肠道逆境环境的损害来维持益生菌的活性，并提高益生菌在肠道的定植能力和生物活性。
Absstract of: CN120241644A
本发明涉及一种多黏菌素B前药纳米粒子及其制备方法与应用。多黏菌素B前药纳米粒子的制备方法，包括：将4‑(羟甲基)苯硼酸频哪醇酯溶于二氯甲烷，加入羰基二咪唑，室温反应，得到活化的4‑(羟甲基)苯硼酸频哪醇酯，并与多黏菌素B和4‑二甲氨基吡啶溶于二甲基亚砜中，室温反应，得到前药PPMB；将卵磷脂溶液、二硬脂酰磷脂酰乙醇胺‑聚乙二醇2000‑马来酰亚胺和二硬脂酰磷脂酰乙醇胺‑聚乙二醇2000加入到水中，然后滴加PPMB甲醇溶液，室温反应，得到多黏菌素B前药纳米粒子。本发明还提供一种所述制备方法制得的多黏菌素B前药纳米粒子及其应用。本发明解决了药物在体内毒性大、靶向性不足的问题。
Absstract of: CN120241640A
本发明提供了一种靶向纳米粒组合物及其应用，具体地，本发明提供了一种靶向的脂质纳米粒组合物，其包括可电离脂质和靶向组分，该药物组合物兼具靶向性和协同效应。一方面，该药物组合物能够特异性地向巨噬细胞递送编码治疗蛋白的mRNA，使得该类细胞能够翻译出活性蛋白，解决因蛋白药物在体内不稳定而无法直接递送的问题。另一方面，该药物组合物能够促进巨噬细胞从M1型向M2型极化，增多的M2型巨噬细胞特异性的摄取更多的药物组合物，由此形成正反馈靶向机制的闭合回路，从而招募更多的药物组合物富集在病变部位，全面提高传递效率和转染效率，实现更高效的治疗效果。
Absstract of: CN120241648A
本申请公开了一种基于姜黄素共晶的脂质纳米颗粒及其制备方法和应用。本申请基于姜黄素共晶的脂质纳米颗粒，包括脂质纳米颗粒包封材料以及包封在其中的姜黄素超分子共晶组合物；脂质纳米颗粒包封材料由可离子化阳离子脂、磷脂、胆固醇和PEG脂组成，可离子化阳离子脂为式一所示结构；姜黄素超分子共晶组合物为姜黄素、左旋肉碱和端部具有羧基的聚乙二醇衍生物形成的超分子共晶。本申请基于姜黄素共晶的脂质纳米颗粒，具有良好的细胞内释放效果，能够更高效的作用于细胞，并且细胞毒性小；本申请的脂质纳米颗粒，对姜黄素的包封效率高，稳定性好，为姜黄素的高效使用提供了一种新的方案和途径。
Absstract of: CN120242073A
本发明公开了一种纳米药物组合物及其制备方法和应用，属于药物制剂领域。本发明的纳米药物组合物包括所述纳米药物组合物的活性物质包括天然生物碱类化合物和肿瘤细胞凋亡诱导因子；所述天然生物碱类药物包括荜茇酰胺，所述肿瘤细胞凋亡诱导因子包括TRAIL；还包括透明质酸盐和PAMAM。制备方法包括：S1、将荜茇酰胺溶解在丙酮溶液中，加入PAMAM溶液得到PP复合物；S2、将PP复合物和TRAIL溶液混合，得到PPT复合物；S3、将PPT复合物和透明质酸溶液混合，得到HPPT。本发明纳米药物组合物在抑制乳腺癌细胞和组织种表现出显著的协同增效作用。
Absstract of: CN120241655A
本发明公开了一种干细胞膜修饰的脂质体纳米载药粒子及其制备方法，属于纳米载药技术领域，具体涉及：芯层，所述芯层为载体和药物，药物负载于载体上，所述载体为脂质载体，脂质载体包括卵磷脂酰胆碱和胆固醇；膜层，所述膜层为干细胞膜，干细胞膜包覆于芯层外；外层，所述外层包括壳聚糖基衍生物；芯层和膜层构成干细胞膜包覆脂质体纳米载药粒子，壳聚糖基衍生物的量为干细胞膜包覆脂质体纳米载药粒子的400‑600wt%。本发明提供了一种稳定性好、酸性肿瘤微环境下药物释放效果好、靶向性好、免疫相容性好、生物安全性好、生物相容性好的干细胞膜修饰的脂质体纳米载药粒子及其制备方法。
Absstract of: CN120242044A
本发明属于生物医药技术领域，涉及一种靶向性的药物递送载体及其制备方法。本发明提供了一种靶向性的药物递送载体包括：载药载体和靶向性多肽；所述载药载体为病毒载体，且所述靶向性多肽的核苷酸与所述病毒载体的衣壳蛋白的核苷酸可操作性地连接；或，所述载药载体为非病毒载体，且所述靶向性多肽通过表面修饰的方式与非病毒载体连接，所述靶向性多肽的氨基酸序列如SEQ ID NO：8‑12、SEQ ID NO：14中任一项所示。本发明通过利用特异性识别生物分子、细胞、组织或器官的靶向性多肽，设计并制备高效的药物递送载体。
Absstract of: AU2023360051A1
The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.
Absstract of: CN120247724A
本发明涉及一种含碳酸酯基的可电离脂质化合物、其制备方法、组合物及应用。所述含碳酸酯基的可电离脂质化合物具有式I所示的结构。所述含碳酸酯基的可电离脂质结合了可生物降解的碳酸酯连接体、疏水尾部以及可调节类型和数量的胺头部，其可用于脾内NK细胞靶向mRNA递送，并且表现出优异的稳定性和极低的体内毒性。#imgabs0#
Absstract of: WO2025140556A1
The present invention provides an ionizable cationic lipid compound having a structure represented by formula (I), which can be used for preparing a lipid nanoparticle (LNP) for the delivery of therapeutic and/or prophylactic agents. The LNP prepared by using the ionizable cationic lipid compound of the present invention has better stability and transfection efficiency, and can efficiently and stably deliver a bioactive substance (comprising nucleic acids, such as mRNA) to a target cell or organ, thereby causing a highly specific antibody response in vivo.
Absstract of: WO2025140590A1
The present invention provides a glycine-containing cationic lipid. The structure of the glycine-containing cationic lipid is shown as general formula (1-A), wherein the definition of each symbol is consistent with that in the description. The glycine-branched cationic lipid has a nitrogen-containing heterocycle as a central branched core, has glycine as a secondary branched core, and has a saturated or unsaturated hydrocarbon group as a tail chain, and has the advantages of low toxicity, low immunogenicity, and high biocompatibility. Glycine contained in the novel cationic lipid of the present invention can provide a tertiary amine structure while serving as the secondary branched core, and form a multi-stage tertiary amine structure together with the nitrogen-containing heterocycle central core, increasing the number of tertiary amines capable of being ionized to produce positive charges. When preparing an LNP, the amount of cationic lipid used is less, which is safer and improves the translation efficiency of nucleic acids.
Absstract of: WO2025140591A1
Provided in the present invention is a nitrogen-containing heterocycle-branched cationic lipid. The structure thereof is as represented by general formula (1), wherein the definition of each symbol is consistent with that described herein. The nitrogen-containing heterocycle-branched cationic lipid has a nitrogen-containing heterocycle as a branched core, an amino acid or an amino acid derivative as a linker arm, and a saturated or unsaturated hydrocarbon group as a tail chain; and has the advantages of low toxicity, low immunogenicity and high biocompatibility. In the new cationic lipid of the present invention, the electropositivity of the nitrogen on the nitrogen-containing heterocycle is delocalized to the whole ring, so that the cationic lipid shows higher transfection efficiency and lower cytotoxicity. The new cationic lipid of the present invention contains one or more biodegradable groups between the nitrogen-containing heterocycle and the hydrophobic tail, and the presence of the degradable groups enables a lipid nanoparticle (LNP) prepared from the cationic lipid to be timely degraded in the endosome, such that the problem in the prior art whereby LNPs prepared from a non-degradable lipid accumulate in the endosome and acidify the endosomal environment, thereby hindering the endosomal escape of a drug molecule (such as a nucleic acid) and thus the drug delivered into a cell not being able to function is solved.
Absstract of: WO2025141521A1
Provided herein are dendritic lipids or pharmaceutically acceptable salts thereof. The dendritic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Nº publicación: WO2025140585A1 03/07/2025
Applicant:
BEIJING CARRIUS BIO LTD [CN]
BEIJING CARRIUS BIO LTD
Absstract of: WO2025140585A1
The present invention provides an ionizable lipid compound, which can target spleen for delivery of biological macromolecules including nucleic acid drugs or nucleic acid vaccines with high efficiency. The present invention also relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and an active molecule, and a pharmaceutical composition comprising the lipid nanoparticle.
BOPI
Electronic site
